Aurobindo Pharma’s recent results were underwhelming, especially on margins. In contrast, peers like Dr. Reddy’s, Cipla, and Sun Pharma have shown strong performance in specialty and complex generics, earning market favor. Choksey favors companies in niche segments—like specialty generics, novel delivery systems, and CRAMS—while steering clear of firms that rely heavily on commoditized generics due to pricing volatility.